Celiac Disease - Pipeline Review, 2019
Table of Content:
1. Introduction
1.1. Report Overview
2. Celiac Disease -
Overview
3. Executive Summary
4. Celiac Disease :
Pipeline Assessment
4.1. By Stage of Development
4.2. By Route of Administration
4.3. By Drug Class
4.4. By Molecule Type
4.5. By Therapy Area / Indication
4.6. By Drug Target
4.7. By Sponsor
5. Celiac Disease:
Company & Drug Profiles
5.1. Clinical Stage
5.1.1.
TIMP-GLIA – COUR Pharmaceutical Development Company, Inc.
5.1.1.1.
Company Overview
5.1.1.2.
Product Description
5.1.1.3.
R&D Status & Development Activities
5.1.1.4.
Mechanism of Action
5.1.1.5.
Molecule Type
5.1.1.6. Stage
of Development
5.1.1.7.
Indications
5.1.1.8. Route
of Administration
5.1.1.9.
Funding
5.1.2. Nexvax2
– ImmusanT, Inc.
5.1.2.1.
Company Overview
5.1.2.2.
Product Description
5.1.2.3.
R&D Status & Development Activities
5.1.2.4.
Mechanism of Action
5.1.2.5.
Molecule Type
5.1.2.6. Stage
of Development
5.1.2.7.
Indications
5.1.2.8. Route
of Administration
5.1.2.9. Funding
5.1.3.
Latiglutenase – Immunogenics, LLC
5.1.3.1.
Company Overview
5.1.3.2.
Product Description
5.1.3.3.
R&D Status & Development Activities
5.1.3.4.
Mechanism of Action
5.1.3.5.
Molecule Type
5.1.3.6. Stage
of Development
5.1.3.7.
Indications
5.1.3.8. Route
of Administration
5.1.3.9.
Funding
5.1.4. Others
5.2. Preclinical
5.2.1. Company
Overview
5.2.2. Product
Description
5.2.3. R&D
Status & Development Activities
5.2.4. Mechanism of Action
5.2.5.
Molecule Type
5.2.6.
Indications
5.2.7. Route
of Administration
5.2.8. Funding
6. Celiac Disease: An
Overview on Dormant & Discontinued Pipeline Candidates
6.1. Overview
6.2. Product Description
6.3. Reason for Discontinuation
7. Celiac Disease:
Additional Key Insights
7.1. Epidemiology Overview:
Celiac Disease
7.2. Current Market Scenario:
Celiac Disease Therapeutics
8. Celiac Disease: News, Press Releases and Conference Details
Note:
1) This Table of Content is tentative and subject to change as the research progresses.
2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.
Healthcare Clients
